Literature DB >> 21983638

β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.

Peter E Clark1, Dina Polosukhina, Harold Love, Hernan Correa, Cheryl Coffin, Elizabeth J Perlman, Mark de Caestecker, Harold L Moses, Roy Zent.   

Abstract

Wilms' tumor (WT) is the most common childhood renal cancer. Although mutations in known tumor-associated genes (WT1, WTX, and CATNB) occur only in a third of tumors, many tumors show evidence of activated β-catenin-dependent Wnt signaling, but the molecular mechanism by which this occurs is unknown. A key obstacle to understanding the pathogenesis of WT is the paucity of mouse models that recapitulate its features in humans. Herein, we describe a transgenic mouse model of primitive renal epithelial neoplasms that have high penetrance and mimic the epithelial component of human WT. Introduction of a stabilizing β-catenin mutation restricted to the kidney is sufficient to induce primitive renal epithelial tumors; however, when compounded with activation of K-RAS, the mice develop large, bilateral, metastatic, multifocal primitive renal epithelial tumors that have the histologic and staining characteristics of the epithelial component of human WT. These highly malignant tumors have increased activation of the phosphatidylinositol 3-kinase-AKT and extracellular signal-regulated kinase pathways, increased expression of total and nuclear β-catenin, and increased downstream targets of this pathway, such as c-Myc and survivin. Thus, we developed a novel mouse model in which activated K-RAS synergizes with canonical Wnt/β-catenin signaling to form metastatic primitive renal epithelial tumors that mimic the epithelial component of human WT.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983638      PMCID: PMC3260797          DOI: 10.1016/j.ajpath.2011.08.006

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  71 in total

1.  Cited1 and Cited2 are differentially expressed in the developing kidney but are not required for nephrogenesis.

Authors:  Scott Boyle; Toshi Shioda; Alan O Perantoni; Mark de Caestecker
Journal:  Dev Dyn       Date:  2007-08       Impact factor: 3.780

2.  Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors.

Authors:  M R Eccles; K Yun; A E Reeve; A E Fidler
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

3.  Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys.

Authors:  D L Schaffner; R Barrios; C Massey; E I Bañez; C N Ou; S Rajagopalan; E Aguilar-Cordova; R M Lebovitz; P A Overbeek; M W Lieberman
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

4.  ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor.

Authors:  J H Pinthus; E Fridman; B Dekel; I Goldberg; K Kaufman-Francis; Z Eshhar; A Harmelin; G Rechavi; O Mor; J Ramon; Y Mor
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

5.  Infrequency of ras, p53, WT1, or RB gene alterations in Wilms tumors.

Authors:  P G Waber; J Chen; P D Nisen
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

6.  Fate mapping using Cited1-CreERT2 mice demonstrates that the cap mesenchyme contains self-renewing progenitor cells and gives rise exclusively to nephronic epithelia.

Authors:  Scott Boyle; Andrew Misfeldt; Kelly J Chandler; Karen K Deal; E Michelle Southard-Smith; Douglas P Mortlock; H Scott Baldwin; Mark de Caestecker
Journal:  Dev Biol       Date:  2007-10-24       Impact factor: 3.582

7.  Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.

Authors:  Jason S Frischer; Jianzhong Huang; Anna Serur; Angela Kadenhe-Chiweshe; Kimberly W McCrudden; Kathleen O'Toole; Jocelyn Holash; George D Yancopoulos; Darrell J Yamashiro; Jessica J Kandel
Journal:  Int J Oncol       Date:  2004-09       Impact factor: 5.650

8.  Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.

Authors:  Michael B Major; Nathan D Camp; Jason D Berndt; Xianhua Yi; Seth J Goldenberg; Charlotte Hubbert; Travis L Biechele; Anne-Claude Gingras; Ning Zheng; Michael J Maccoss; Stephane Angers; Randall T Moon
Journal:  Science       Date:  2007-05-18       Impact factor: 47.728

9.  Pattern of expression of gamma-glutamyl transpeptidase in rat liver and kidney during development: study by immunochemistry and in situ hybridization.

Authors:  E Jacquemin; F Bulle; J F Bernaudin; M Wellman; R N Hugon; G Guellaen; M Hadchouel
Journal:  J Pediatr Gastroenterol Nutr       Date:  1990-07       Impact factor: 2.839

10.  Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor.

Authors:  Akiko Yokoi; Kimberly W McCrudden; Jianzhong Huang; Eugene S Kim; Samuel Z Soffer; Jason S Frischer; Anna Serur; Tamara New; Jenny Yuan; Mahesh Mansukhani; Kathleen O'toole; Darrell J Yamashiro; Jessica J Kandel
Journal:  J Pediatr Surg       Date:  2003-11       Impact factor: 2.545

View more
  19 in total

1.  Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage.

Authors:  Kelli M Sas; Hong Yin; Wayne R Fitzgibbon; Catalin F Baicu; Michael R Zile; Stacy L Steele; May Amria; Takamitsu Saigusa; Jason Funk; Marlene A Bunni; Gene P Siegal; Brian J Siroky; John J Bissler; P Darwin Bell
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-22

2.  A Murine Model of K-RAS and β-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor.

Authors:  Yajun Yi; Dina Polosukhina; Harold D Love; Austin Hembd; Michael Pickup; Harold L Moses; Harold N Lovvorn; Roy Zent; Peter E Clark
Journal:  J Urol       Date:  2015-04-29       Impact factor: 7.450

3.  Wilms tumor-suppressing peptide inhibits proliferation and induces apoptosis of Wilms tumor cells in vitro and in vivo.

Authors:  Wei Zhao; Juan Li; Ping Li; Fei Guo; Pengfei Gao; Junjie Zhang; Zechen Yan; Lei Wang; Da Zhang; Pan Qin; Guoqiang Zhao; Jiaxiang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-28       Impact factor: 4.553

4.  Depletion of K-Ras promotes proteasome degradation of survivin.

Authors:  Awet Tecleab; Saïd M Sebti
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

5.  Multi-organ Mapping of Cancer Risk.

Authors:  Liqin Zhu; David Finkelstein; Culian Gao; Lei Shi; Yongdong Wang; Dolores López-Terrada; Kasper Wang; Sarah Utley; Stanley Pounds; Geoffrey Neale; David Ellison; Arzu Onar-Thomas; Richard James Gilbertson
Journal:  Cell       Date:  2016-08-25       Impact factor: 41.582

6.  β-Catenin directs the transformation of testis Sertoli cells to ovarian granulosa-like cells by inducing Foxl2 expression.

Authors:  Yaqiong Li; Lianjun Zhang; Yuqiong Hu; Min Chen; Feng Han; Yan Qin; Min Chen; Xiuhong Cui; Shuguang Duo; Fuchou Tang; Fei Gao
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

7.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

8.  FXR1 expression domain in Wilms tumor.

Authors:  Hannah M Phelps; Janene M Pierce; Andrew J Murphy; Hernan Correa; Jun Qian; Pierre P Massion; Harold N Lovvorn
Journal:  J Pediatr Surg       Date:  2019-02-28       Impact factor: 2.545

Review 9.  The Vanderbilt O'Brien Kidney Center.

Authors:  Ambra Pozzi; Raymond C Harris
Journal:  Am J Physiol Renal Physiol       Date:  2020-12-28

10.  N -Methyl- N -nitrosourea-induced Renal Tumors in Rats: Immunohistochemical Comparison to Human Wilms Tumors.

Authors:  Katsuhiko Yoshizawa; Yuichi Kinoshita; Yuko Emoto; Ayako Kimura; Norihisa Uehara; Takashi Yuri; Nobuaki Shikata; Airo Tsubura
Journal:  J Toxicol Pathol       Date:  2013-07-10       Impact factor: 1.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.